April 11, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jason Drory
Re: | AN2 Therapeutics, Inc. |
Registration Statement on Form S-3
File No. 333-271174
Acceleration Request
Requested Date: April 13, 2023
Requested Time: 4:00 PM Eastern Daylight Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the Registrant) hereby requests that the U.S. Securities and Exchange Commission (the Commission) take appropriate action to cause the Registration Statement on Form S-3 (File No. 333-271174) (the Registration Statement) to become effective on April 13, 2023 at 4:00 p.m. Eastern Daylight Time, or as soon as practicable thereafter, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission (the Staff). The Registrant hereby authorizes Josh Seidenfeld of Cooley LLP, or, in his absence, Sally Kay of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Josh Seidenfeld of Cooley LLP, counsel to the Registrant, at (650) 843-5862, or, in his absence, Sally Kay of Cooley LLP, counsel to the Registrant at (650) 843-5582.
Very truly yours, | ||
AN2 Therapeutics, Inc. | ||
By: | /s/ Eric Easom | |
Eric Easom | ||
Chief Executive Officer |
cc: | Josh Seidenfeld, Cooley LLP |
Sally Kay, Cooley LLP
Anitha Anne, Cooley LLP